Company will not pursue additional development of APL-9 for the treatment of severe COVID-19 Interim review by independent data monitoring committee (DMC) found no meaningful reduction in the overall mortality rate in Phase 1/2 study No safety signals were observed by the DMC.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.